Finance

Lists
524372:BOM
Orchid Pharma Ltd
₹980,00
-0,15%
(-1,45) 1D
9 Okt., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 524372...
Open
₹982,85
High
₹1 001,00
Low
₹960,00
Mkt. cap
58,36 mjd
Avg. vol.
7,18 k
Volume
4,76 k
52-wk high
₹1 142,65
52-wk low
₹471,30
No. of employees
1 k
Open
₹982,85
High
₹1 001,00
Low
₹960,00
Mkt. cap
58,36 mjd
Avg. vol.
7,18 k
Volume
4,76 k
52-wk high
₹1 142,65
52-wk low
₹471,30
No. of employees
1 k
News stories
From web sources and news partners
Profile
Orchid Pharma Limited is an Indian pharmaceutical company based in Chennai. It was founded by Kailasam Raghavendra Rao on 1 July 1992. Orchid Pharma is the only pharma company in India to have discovered a New Drug Enmetazobactam which is now approved in United States, Europe and India. Wikipedia
About Orchid Pharma Ltd
CEO-
Employees1,17 k
Founded1992
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
1,94 mjd
2,07 mjd
6,59 mjd
3,04 mjd
Cost of goods sold
1,33 mjd
1,43 mjd
5,03 mjd
2,04 mjd
Cost of revenue
1,33 mjd
1,43 mjd
5,03 mjd
2,04 mjd
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
248,51 m
241,28 m
502,27 m
280,38 m
Operating expense
713,95 m
715,86 m
1,40 mjd
968,16 m
Total operating expenses
2,04 mjd
2,15 mjd
6,43 mjd
3,01 mjd
Operating income
-103,77 m
-74,65 m
163,81 m
30,51 m
Other non operating income
107,74 m
56,09 m
-238,03 m
18,28 m
EBT including unusual items
-57,24 m
-126,14 m
131,94 m
32,97 m
EBT excluding unusual items
-57,24 m
-55,01 m
54,86 m
32,97 m
Income tax expense
-
-
17,00 k
723,00 k
Effective tax rate
-
-
0,01%
2,19%
Other operating expenses
376,43 m
384,29 m
419,31 m
578,29 m
Net income
-57,24 m
-126,14 m
131,92 m
32,24 m
Net profit margin
-2,96%
-6,09%
2,00%
1,06%
Earnings per share
-1,13
-1,08
4,58
0,54
Interest and investment income
-
-
101,25 m
-
Interest expense
-37,32 m
-31,78 m
-
-22,30 m
Net interest expenses
-37,32 m
-31,78 m
101,25 m
-22,30 m
Depreciation and amortization charges
89,01 m
90,29 m
166,61 m
109,49 m
EBITDA
-15,99 m
10,45 m
269,63 m
119,14 m
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google-programme